Isotretinoin delays bone development in young rats.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
42 citations
,
May 2007 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism” Testosterone can build muscle and bone without enlarging the prostate when a specific enzyme is blocked.
February 2024 in “Practical Diabetes” Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.
5 citations
,
August 2021 in “Journal of biological chemistry/The Journal of biological chemistry” Retinoic acid affects male and female muscle energy use and function differently.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
24 citations
,
September 2005 in “Journal of Cellular Biochemistry” Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.
12 citations
,
October 1978 in “PubMed” Ro 10-9359 is an effective treatment for severe psoriasis but can cause side effects.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
143 citations
,
May 2002 in “PubMed” LGD1069 effectively prevents breast tumors in mice without toxicity.
26 citations
,
January 1994 in “Hormone and Metabolic Research” Taking spironolactone and linestrenol for androgen excess can lead to lower bone density in young women.
April 2026 in “The Journal of Steroid Biochemistry and Molecular Biology” August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
January 2014 in “Reactions Weekly” June 2014 in “Reactions Weekly” August 2011 in “Reactions Weekly” December 2024 in “Reactions Weekly” November 2014 in “Reactions Weekly” July 2014 in “Reactions Weekly” August 2013 in “Reactions Weekly” January 2013 in “Reactions Weekly” December 2012 in “Reactions Weekly” August 2012 in “Reactions Weekly” August 2011 in “Reactions Weekly” May 2011 in “Reactions Weekly” April 2011 in “Reactions Weekly” March 2011 in “Reactions Weekly” April 2010 in “Reactions Weekly” September 2009 in “Reactions Weekly” August 2009 in “Reactions Weekly”